Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc.

NTHI·NASDAQ

$4.35

-4.2%
HealthcareBiotechnology

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

At a Glance

Live Snapshot
Market Cap$86.98M
EPS-3.2300
P/E Ratio-1.35
Earnings Date06/03/2026

nthi

Net Common Stock Issuance

Last Annual Value

17.16M

3-Year CAGR

93%

5-Year CAGR

%

10-Year CAGR

%

Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc. Competitors Analysis of Net Common Stock Issuance

NTHI · NASDAQ
CompanyNet Common Stock Issuance
CAGR 3Y
CAGR 5Y
CAGR 10Y
17.16M
3265.8%N/AN/A 
658.00K
408.6%-52.2%-21.7%
IVVD logo
Invivyd, Inc.
NASDAQ:IVVD
215.63M
N/A-8.2%N/A
OABI logo
OmniAb, Inc.
NASDAQ:OABI
28.36M
N/AN/AN/A
86.82M
57.5%57.3%N/A
174.67M
133.7%27.0%102.2%
77.43M
1031.8%4.3%16.6%
9.89M
-37.0%133.4%N/A
74.01M
69.8%22.3%52.2%
82.90M
N/AN/A82.0%
71.97M
556.8%N/AN/A
Neonc Technologies Holdings, Inc.

Neonc Technologies Holdings, Inc. Fair Value Envelope

NTHI · NASDAQ

Our analysis suggests that NTHI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.35, this represents a potential HIDDEN relative to our calculated worth for Neonc Technologies Holdings, Inc..

Intrinsic Value
Current Price: $4.35